natgillin/translations-raw huggingface dataset:
Therefore, it is important that men also use effective contraception. 
Zato je pomembno, da tudi moški uporabljajo učinkovito kontracepcijo.
Take your next normal dose at its scheduled time. 
Naslednji običajni odmerek vzemite ob predvidenem času.
• you have ever had heart problems - your doctor may want to keep a close eye on you. 
• če ste kdaj imeli težave s srcem - zdravnik vas bo morda želel skrbno spremljati.
• Put the tablet in a glass. 
• Tableto dajte v kozarec.
This is because some medicine may remain in your body, (see advice on contraception below). 
Nekaj zdravila namreč lahko ostane v telesu (glejte nasvet o kontracepciji, spodaj).
Do not give this medicine to children or adolescents under the age of 18 years. 
Tega zdravila ne dajajte otrokom in mladostnikom, mlajšim od 18 let.
• You can take this medicine with or without food. 
• To zdravilo lahko vzamete s hrano ali brez nje.
If you forget a dose, take it as soon as you remember it. 
Če pozabite vzeti odmerek, ga vzemite, čim se spomnite.
(Findings based on test results presented as CTCAE grade shifts) 
(Izsledki na podlagi rezultatov preiskav, prikazani kot premiki stopnje CTCAE)
This is more likely in areas exposed to the sun. 
Te spremembe so verjetnejše na predelih, izpostavljenih soncu.
This is because it is not known if there is a risk to your baby. 
Ni namreč znano, ali obstaja kakšno tveganje za otroka.
No other liquids should be added. 
Drugih tekočin se ne sme dodajati.
• Stir thewater until the tablet breaks up into very small pieces -the tablet will not completely dissolve. 
• Vodo mešajte, dokler se tableta ne razpusti v zelo majhne delce - tableta se ne bo popolnoma raztopila.
Your doctor will discuss appropriate treatment options with you. 
Zdravnik se bo z vami pogovoril o primernih možnostih zdravljenja.
The types of adverse events reported were similar regardless of age. 
Vrste poročanih neželenih učinkov so bile podobne ne glede na starost.
Of 556 patients, 200 patients had available baseline brain scans. 
Od 556 bolnikov jih je 200 imelo na voljo izhodiščne posnetke možganov.
Duration of Response (DoR) 
Trajanje odziva (DoR)
If you are able to become pregnant, you must use effective contraception. 
Če bi lahko zanosili, morate uporabljati učinkovito kontracepcijo.
See ‘Contraception - information for women and men' below. 
Glejte “Kontracepcija - informacije za ženske in moške”, spodaj.
Do not stop taking this medicine - talk to your doctor first. 
Ne prenehajte jemati tega zdravila - najprej se posvetujte z zdravnikom.
Represents the incidence of laboratory findings, not of reported adverse events. 
Predstavlja pojavnost laboratorijskih izvidov, ne poročanih neželenih učinkov.
• Add 50 mL (about two-thirds of a tumblerful) of still (non-fizzy) water - do not use any other liquids. 
• Dodajte 50 ml (približno dve tretjini kozarca) vode (brez mehurčkov) - ne uporabljajte nobenih drugih tekočin.
• Do not use any pack that is damaged or shows signs of tampering. 
• Ne uporabite pakiranj, ki so poškodovana ali kažejo znake, da jih je že kdo odpiral.
TAGRISSO can be taken with or without food at the same time each day. 
Zdravilo TAGRISSO je mogoče vzeti s hrano ali brez nje, vsak dan ob istem času.
Contraception - information for women and men You must use effective contraception during treatment. 
Kontracepcija - informacije za ženske in moške Med zdravljenjem morate uporabljati učinkovito kontracepcijo.
It is important to take this medicine every day, for as long as your doctor prescribes it for you. 
Pomembno je, da to zdravilo jemljete vsak dan toliko časa, kot vam predpiše zdravnik.
Because of this defect, other protein kinase medicines may no longer work. 
Zaradi te napake se lahko zgodi, da drugi zaviralci protein-kinaze ne delujejo več.
Reintroduction of TAGRISSO should be considered only after careful consideration of the individual patient's benefits and risk. 
Ponovna uvedba zdravila TAGRISSO pride v poštev le po skrbnem pretehtanju koristi in tveganj pri posameznem bolniku.
However, with current available data, alternative metabolic pathways cannot be fully ruled out. 
Vseeno pa s podatki, ki so trenutno na voljo, ni možno izključiti alternativnih metabolnih poti.
• To make sure you have taken all of the medicine, rinse the glass thoroughly with another 50 mL of water and drink it. 
• Da boste zaužili zares vse zdravilo, kozarec dobro splaknite z dodatnimi 50 ml vode in jo popijte.
Most cases improved or resolved with interruption of treatment. 
Večina primerov se je po prenehanju zdravljenja izboljšala ali je izginila.
• you have severe peeling of your skin. 
• če imate hudo luščenje kože.
Discuss with your doctor the most appropriate methods of contraception. 
zdravnikom se posvetujte o najprimernejših načinih kontracepcije.
A risk for decreased exposure of hormonal contraceptives cannot be excluded. 
Tveganja za manjšo izpostavljenost hormonskim kontraceptivom ni mogoče izključiti.
• Take TAGRISSO every day at the same time. 
• Zdravilo TAGRISSO vzemite vsak dan ob istem času.
Before initiating treatment, patients should be advised of signs and symptoms of SJS. 
Pred uvedbo zdravljenja je treba bolnike seznaniti z znaki in simptomi SJS.
Randomisation was stratified by ethnicity (Asian and non-Asian). 
Randomizacija je bila stratificirana po etnični pripadnosti (azijsko in neazijsko poreklo).
Appetite Loss 
Izguba apetita
• Oral hormonal contraceptive pill- used to prevent pregnancy. 
• peroralne hormonske kontracepcijske tablete - uporabljajo se za preprečevanje nosečnosti.
• you have sudden difficulty in breathing together with a cough or fever. 
• če se vam nenadoma pojavi težko dihanje skupaj s kašljem ali vročino.
Assessment of EGFR mutation status 
Ocena stanja mutacije EGFR
Tell your doctor if your skin or nail problems get worse. 
Zdravnika morate obvestiti, če se vam težave s kožo ali nohti poslabšajo.
Pregnancy - information for women 
Nosečnost - informacije za ženske
Age and body weight 
Starost in telesna masa
• Reduction in the number of white blood cells (leukocytes, lymphocytesor neutrophils). 
• Zmanjšanje števila belih krvnih celic (levkocitov, limfocitov ali nevtrofilcev).
Close monitoring is recommended in these patients (see section 4.8). 
Pri teh bolnikih je priporočeno skrbno spremljanje (glejte poglavje 4.8).
Based on unconfirmed response 
Na podlagi nepotrjenega odziva.
Dose reduction was required in 0.2% of patients and dose interruption in 1.4%. 
Zmanjšanje odmerka je bilo potrebno pri 0,2 % bolnikov, prekinitev uporabe pa pri 1,4 % bolnikov.
Compliance over the first 9 months was generally high (≥70%) and similar in both arms. 
Sodelovanje bolnikov je bilo v prvih 9 mesecih na splošno visoko (≥ 70 %) in v obeh skupinah podobno.
QTc interval prolongation 
Podaljšanje intervala QTc
• The recommended dose is one 80 mg tablet each day. 
• Priporočeni odmerek je ena 80 mg tableta vsak dan.
TAGRISSO should not be used during pregnancy unless the clinical condition of the woman requires treatment with osimertinib. 
Zdravila TAGRISSO se med nosečnostjo ne sme uporabljati, razen če klinično stanje bolnice zahteva zdravljenje z osimertinibom.
• you have a history of eye problems. 
• če ste kdaj imeli težave z očmi.
An additional half a glass of water should be added to ensure that no residue remains and then immediately swallowed. 
Dodati mora še dodatnega pol kozarca vode in tako zagotoviti, da ne ostane nič zdravila; dodatno vodo mora takoj popiti.
• Reduction in the number of platelets in the blood. 
• Zmanjšanje števila trombocitov v krvi.
The safety and efficacy of this medicinal product has not been established in patients with severe hepatic impairment. 
Varnost in učinkovitost tega zdravila nista ugotovljeni pri bolnikih s hudo okvaro jeter.
Patients should be advised to use effective contraception for the following periods after completion of treatment with this medicinal product: at least 2 months for females and 4 months for males. 
Bolnicam oz. bolnikom je treba naročiti, da morajo uporabljati učinkovito kontracepcijo tudi še po koncu zdravljenja s tem zdravilom, in sicer ženske vsaj še 2 meseca in moški še 4 mesece.
These findings were seen at clinically relevant plasma concentrations. 
To so opažali ob klinično pomembnih plazemskih koncentracijah.
Most adverse reactions were Grade 1 or 2 in severity. 
Večina neželenih učinkov je bila glede na resnost 1. ali 2. stopnje.
Osimertinib is eliminated mainly via the liver. 
Osimertinib se izloča predvsem preko jeter.
TAGRISSO works by blocking EGFR and may help to slow or stop your lung cancer from growing. 
Zdravilo TAGRISSO deluje tako, da zavira EGFR in lahko pomaga upočasniti ali ustaviti rast pljučnega raka.
Discontinuation due to adverse reactions was 4.3%. 
Ukinitev uporabe zdravila zaradi neželenih učinkov je bilo 4,3 %.
If you take more TAGRISSO than you should If you take more than your normal dose, contact your doctor or nearest hospital straight away. 
Če ste vzeli večji odmerek zdravila TAGRISSO, kot bi smeli Če vzamete odmerek, večji od običajnega odmerka, se nemudoma posvetujte z zdravnikom ali pojdite v najbližjo bolnišnico.
CIOMS descriptor/ overall frequency (all CTCAE grades) 
Izraz po MedDRA Deskriptor CIOMS/celotna pogostnost (vse stopnje CTCAE)
The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity. 
Priporočeni odmerek je 80 mg osimertiniba enkrat na dan do napredovanja bolezni ali nesprejemljivih toksičnih učinkov.
Effects of osimertinib on P-gp and BCRP 
Vplivi osimertiniba na P-gp in BCRP
Overall survival data were not mature at the time of this initial OS analysis. 
Podatki o celokupnem preživetju ob času te uvodne analize celokupnega preživetja še niso bili dozoreli.
In addition, the corresponding frequency category for each adverse reaction is based on the CIOMS III convention and is defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from available data). 
Poleg tega ustrezne kategorije pogostnosti za vsak neželeni učinek temeljijo na konvenciji CIOMS III in so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
This includes herbal medicines and medicines obtained without a prescription. 
To velja tudi za zdravila rastlinskega izvora in druga zdravila, ki ste jih dobili brez recepta.
TAGRISSO may affect how well the following medicines work and/or increase side effects of these medicines: 
Zdravilo TAGRISSO lahko vpliva na to, kako dobro delujejo naslednja zdravila in/ali poveča njihove neželene učinke:
All cases were isolated incidents of patients taking an additional daily dose of TAGRISSO in error, without any resulting clinical consequences. 
Vsi primeri so bili posamični dogodki pri bolnikih, ki so pomotoma vzeli dodaten dnevni odmerek zdravila TAGRISSO, in niso imeli nobenih kliničnih posledic.
However, if it is less than 12 hours until your next dose is due, skip the missed dose. 
Če pa je do naslednjega odmerka manj kot 12 ur, pozabljeni odmerek izpustite.
Represents the incidence of patients who had a QTcF prolongation >500msec. 
Predstavlja incidenco bolnikov s podaljšanjem QTcF > 500 msec.
If you have any questions about how this medicine works or why this medicine has been prescribed for you, ask your doctor. 
Če imate vprašanja o tem, kako deluje to zdravilo ali zakaj ste ga dobili, vprašajte zdravnika.
There are no data on the effect of TAGRISSO on human fertility. 
Podatkov o vplivu zdravila TAGRISSO na plodnost pri človeku ni.
TAGRISSO as monotherapy is indicated for: 
Zdravilo TAGRISSO je kot monoterapija indicirano za:
Frequency of CTCAE grade 3 or higher 
Pogostnost 3. ali višje stopnje po CTCAE
The tablet should be swallowed whole with water and it should not be crushed, split or chewed. 
Tableto je treba zaužiti celo z vodo in se je ne sme drobiti, lomiti ali gristi.
It should be dropped in the water, without crushing, stirred until dispersed and immediately swallowed. 
Mora jo dati v vodo (ne da bi jo zdrobil), jo mešati, dokler se ne dispergira, in jo zaužiti takoj.
• If you develop watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. 
• Če se vam pojavijo solzenje, občutljivost na svetlobo, bolečine v očesu, pordelost očesa ali spremembe vida.
Further catalyzing enzymes have not been identified. 
Dodatnih katalizacijskih encimov niso odkrili.
One event (0.1%) led to discontinuation. 
En primer (0,1 %) je povzročil prenehanje uporabe zdravila.
If a test has shown that your cancer has certain changes (mutations) in a gene called ‘EGFR' (epidermal growth factor receptor) and has spread to your other lung or other organs, your cancer is likely to respond to treatment with TAGRISSO. 
Če je preiskava pokazala, da ima vaš rak določene spremembe (mutacije) gena, imenovanega "EGFR" (receptor za epidermalni rastni faktor), in se vam je razširil na drugo pljučno krilo ali v druge organe, se bo vaš rak verjetno odzval na zdravljenje z zdravilom TAGRISSO.
No dosage adjustment is required due to patient age, body weight, gender, ethnicity and smoking status (see section 5.2). 
Odmerka ni treba prilagoditi glede na bolnikovo starost, telesno maso, spol, etnično pripadnost ali kadilski status (glejte poglavje 5.2).
Severe renal impairment may influence the elimination of hepatically eliminated medicinal products. 
Huda okvara ledvic lahko vpliva na izločanje zdravil, ki se odstranjujejo preko jeter.
Swallow the tablet whole with water. 
Tableto zaužijte celo z vodo.
• If necessary, your doctor may reduce your dose to one 40 mg tablet each day. 
• Po potrebi vam zdravnik lahko odmerek zmanjša na eno 40 mg tableto vsak dan.
If dose reduction is necessary, then the dose should be reduced to 40 mg taken once daily. 
V primeru potrebe po zmanjšanju odmerka je treba odmerek zmanjšati na 40 mg enkrat na dan.
These exposure changes due to body weight or baseline albumin differences are not considered clinically relevant. 
Te spremembe izpostavljenosti zaradi razlik v telesni masi ali izhodiščni koncentraciji albumina ne veljajo za klinično pomembne.
Adverse reactions are listed according to system organ class (SOC) in MedDRA. 
Neželeni učinki so navedeni po organskih sistemih (SOC - system organ class) MedDRA.
Patients with CLcr less than 15 mL/min were not included in the clinical trials. 
Bolniki z očistkom kreatinina manj kot 15 ml/min niso bili vključeni v klinična preizkušanja.
The European Medicines Agency has waived the obligation to submit the results of studies with TAGRISSO in all subsets of the paediatric population in NSCLC (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom TAGRISSO za vse podskupine pediatrične populacije pri NSCLC (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Osimertinib may increase the exposure of breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) substrates. 
Osimertinib lahko poveča izpostavljenost substratom BCRP (breast cancer resistant protein) in P-glikoproteina (P-gp).
Objective response rates by BICR above 50% were observed in all predefined subgroups analysed, including line of therapy, ethnicity, age and region. 
Po BICR ocenjen objektivni delež odziva nad 50 % je bil opažen v vseh vnaprej opredeljenih analiziranih podskupinah, vključno glede na linijo zdravljenja, etnično pripadnost, starost in regijo.
The AUC and Cmax increased dose proportionally over 20 to 240 mg dose range. 
AUC in Cmax sta se v razponu odmerkov od 20 do 240 mg povečevali sorazmerno z odmerkom.
Seventy-two percent (72%) of patients were never smokers, 100% of patients had a World Health Organization (WHO) performance status of 0 or 1. 
Dvainsedemdeset odstotkov (72 %) bolnikov ni nikoli kadilo, 100 % bolnikov je imelo stanje zmogljivosti 0 ali 1 po Svetovni zdravstveni organizaciji (WHO - World Health Organization).
If the patient is unable to swallow the tablet, the tablet may first be dispersed in 50 mL of non-carbonated water. 
Če bolnik tablete ne more pogoltniti, lahko tableto dispergira v 50 ml negazirane vode.
The dispersion and residues should be administered within 30 minutes of the addition of the tablets to water. 
Disperzijo in ostanke zdravila je treba bolniku dati v 30 minutah po tem, ko so bile tablete dane v vodo.
Elderly patients (>65 years) or patients with low body weight (<50 kg) may be at increased risk of developing adverse events of Grade 3 or higher. 
Pri starejših bolnikih (> 65 let) ali bolnikih z nizko telesno maso (< 50 kg) je lahko prisotno povečano tveganje za pojav neželenih učinkov 3. ali višje stopnje.
Name and address of the manufacturer responsible for batch release AstraZeneca AB 
Ime in naslov izdelovalca, odgovornega za sproščanje serij AstraZeneca AB
Cardiac QTc interval greater than 500 msec on at least 2 separate ECGs 
Interval QTc je več kot 500 msec na vsaj 2 ločenih posnetkih EKG
Thirty-one percent (31%) (N=129) had received 1 prior line of therapy (EGFR-TKI treatment only), 69% (N=282) had received 2 or more prior lines. 
Enaintrideset odstotkov (31 %) (n = 129) je prejelo 1 predhodno linijo zdravljenja (le zdravljenje z EGFR-TKI) in 69 % (n = 282) jih je prejelo 2 ali več predhodnih linij.
Median follow-up time was 15.0 months for patients receiving TAGRISSO and 9.7 months for patients receiving EGFR TKI comparator 
Mediani čas spremljanja je bil 15,0 mesecev pri bolnikih, ki so prejemali zdravilo TAGRISSO, in 9,7 meseca pri bolnikih, ki so prejemali primerjalni EGFR TKI.
Tell your doctor straight away if you notice the serious side effects listed above. 
Zdravnika takoj obvestite, če opazite zgoraj opisane resne neželene učinke.
• Efavirenz and etravirine - used to treat HIV infections/AIDS. 
• efavirenz in etravirin - uporabljata se za zdravljenje okužbe s HIV/aidsa.
Intestinal inhibition of UGT1A1 is possible but the clinical impact is unknown. 
Zavrtje UGT1A1 v črevesu je možno, a njegov klinični vpliv ni znan.
The safety and efficacy of TAGRISSO in children or adolescents aged less than 18 years have not been established. 
Varnost in učinkovitost zdravila TAGRISSO nista dokazani pri otrocih in mladostnikih, mlajših od 18 let.
5 CTCAE grade 5 events (fatal) were reported. 
Poročali so o 5 primerih dogodkov 5. stopnje (smrtni izid) po CTCAE.
Your doctor will decide with you whether you should carry on taking TAGRISSO. 
Zdravnik bo presodil, ali naj še naprej jemljete zdravilo Tagrisso.
Tell your doctor if your diarrhoea does not go away or becomes severe. 
Zdravnika morate obvestiti, če driska ne mine ali če postane huda.
Osimertinib pharmacokinetic parameters have been characterised in healthy subjects and NSCLC patients. 
Farmakokinetične parametre osimertiniba so raziskali pri zdravih osebah in bolnikih z NSCLC.
Do not breast-feed while taking this medicine. 
Dojenje Med jemanjem tega zdravila ne dojite.
The median time to onset of ILD or ILD-like adverse reactions was 85 days (see section 4.4). 
Mediani čas do pojava IBP ali njej podobnih neželenih učinkov je bil 85 dni (glejte poglavje 4.4).
• The other ingredients are mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, sodium stearyl fumarate, polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, yellow iron oxide, red iron oxide, black iron oxide (see section 2 “Information on other ingredients in this medicine”). 
• Druge sestavine zdravila so manitol, mikrokristalna celuloza, nizkosubstituirana hidroksipropilceluloza, natrijev stearilfumarat, polivinilalkohol, titanov dioksid, makrogol 3350, smukec, rumeni železov oksid, rdeči železov oksid, črni železov oksid (glejte poglavje 2 “Informacije o drugih sestavinah tega zdravila”).
The main metabolic pathway of osimertinib was oxidation and dealkylation. 
Glavna pot presnove osimertiniba je oksidacija in dealkilacija.
One event was reported in a post-marketing study, and the frequency has been derived from the FLAURA and AURA studies and the post-marketing study (N=4720). 
V študiji po prihodu zdravila na trg je bil poročan en dogodek, pogostnost pa je ugotovljena na podlagi študij FLAURA in AURA ter študije po prihodu zdravila na trg (N = 4720).
The safety and efficacy of this medicinal product has not been established in patients with end-stage renal disease [creatinine clearance (CLcr) <15 mL/min, calculated by the Cockcroft and Gault equation], or on dialysis. 
Varnost in učinkovitost tega zdravila nista ugotovljeni pri bolnikih s končno odpovedjo ledvic (očistek kreatinina < 15 ml/min, izračunan po Cockroft-Gaultovi enačbi) in pri bolnikih na dializi.
• Rifabutin or rifampicin - used for tuberculosis (TB). 
• rifabutin ali rifampicin - uporabljata se za zdravljenje tuberkuloze (TBC).
ECGs: Electrocardiograms; QTc: QT interval corrected for heart rate 
EKG: elektrokardiogram, QTc: interval QT, korigiran glede na srčno frekvenco
These effects were seen at a maternally tolerated dose of 20 mg/kg where exposure was equivalent to the human exposure at the recommended dose of 80 mg daily (based on total AUC). 
Te učinke so opažali ob maternalno toleriranem odmerku 20 mg/kg, ko je bila izpostavljenost enakovredna izpostavljenosti človeka ob priporočenem odmerku 80 mg na dan (na podlagi celotne AUC).
Exposure at doses of 20 mg/kg and above during organogenesis caused reduced foetal weights but no adverse effects on external or visceral foetal morphology. 
Izpostavljenost ob odmerkih 20 mg/kg ali več med obdobjem organogeneze je povzročila zmanjšano telesno maso plodov, ni pa imela neželenih učinkov na zunanjo ali visceralno morfologijo plodov.
Target organ Adverse reaction 
Ciljni organ Neželeni učinek
Patients received study therapy until intolerance to therapy, or the investigator determined that the patient was no longer experiencing clinical benefit. 
Bolniki so prejemali študijsko zdravljenje, dokler se ni pojavilo neprenašanje zdravljenja ali dokler raziskovalec ni ugotovil, da zdravljenje bolniku klinično ne koristi več.
Chemotherapy consisted of pemetrexed 500 mg/m2 with carboplatin AUC5 or pemetrexed 500 mg/m2 with cisplatin 75 mg/m2 on Day 1 of every 21-day cycle for up to 6 cycles. 
Kemoterapija je obsegala pemetreksed 500 mg/m2 s karboplatinom AUC5 ali pemetreksed 500 mg/m2 s cisplatinom 75 mg/m2 1. dan vsakega 21-dnevnega ciklusa in do 6 ciklusov.
• Modafinil -used for sleep disorders. 
• modafinil - uporablja za zdravljenje težav s spanjem.
Until additional data become available, use in patients with severe hepatic impairment is not recommended (see section 5.2). 
Dokler ni na voljo dodatnih podatkov, uporaba pri bolnikih s hudo okvaro jeter ni priporočljiva (glejte poglavje 5.2).
• Rosuvastatin - used to lower cholesterol. 
• rosuvastatin - uporablja se za zmanjševanje koncentracije holesterola.
When possible, the use of osimertinib in patients with congenital long QT syndrome should be avoided. 
Uporabi osimertiniba se je treba pri bolnikih s prirojenim sindromom dolgega intervala QT izogniti, če je le mogoče.
• asthe first medicine you receive for your cancer or 
• kot prvo zdravilo za zdravljenje raka, ali
If you have trouble swallowing the tablet, you can mix it in water: 
Če tableto težko pogoltnete, jo lahko zmešate z vodo.
Haematological events 
Hematološki dogodki
The OS analysis was not adjusted for the potentially confounding effects of crossover (94 [67%] patients on the chemotherapy arm received subsequent osimertinib treatment). 
Celokupna analiza ni bila prilagojena za morebitne moteče učinke navzkrižnega prehoda (94 [67 %] bolnikov v skupini s kemoterapijo je pozneje prejemalo osimertinib).
Low body weight 
Nizka telesna masa
Randomisation was stratified by EGFR mutation type (Ex19del or L858R) and ethnicity (Asian or non-Asian). 
Randomizacija je bila stratificirana glede na tip mutacije EGFR (Ex19del ali L858R) in glede na etnično pripadnost (azijska ali neazijska).
• Bosentan - used for high blood pressure in the lungs. 
• bosentan - uporablja se za zdravljenje visokega krvnega tlaka v pljučih.